Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy

We have evaluated the efficacy of targeting the toxic, oligomeric form of tau protein by passive immunotherapy in a mouse model of synucleinopathy. Parkinson ’s disease and Lewy body dementia are two of the mos...

Source: Molecular Neurodegeneration - March 15, 2018 Category: Neurology Authors: Julia E. Gerson, Kathleen M. Farmer, Natalie Henson, Diana L. Castillo-Carranza, Mariana Carretero Murillo, Urmi Sengupta, Alan Barrett and Rakez Kayed Tags: Research article Source Type: research